LAURA DANIEL: Open Payments
NPI 1952634248 · DADEVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$562 in 32 payments from 10 companies in 2025. Trend: 2023 $750 · 2024 $704 · 2025 $562
Food & beverage: $562
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $191 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| GlaxoSmithKline, LLC. | 4 | $75 |
| ABBVIE INC. | 3 | $57 |
| Lundbeck LLC | 2 | $40 |
| Novo Nordisk Inc | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Amgen Inc. | 1 | $14 |
Products named: Kerendia, TRELEGY ELLIPTA, VRAYLAR, AIRSUPRA, REXULTI, Ozempic, CAPLYTA, INGREZZA.
Industry payments across AL — which companies pay providers there.
